2019 Future of Autism R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments
The global demand for Autism treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Autism pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Autism pipeline companies from advancing their products into Phase 3 or Phase 4.
Autism Report Description-
The 2019 pipeline study on Autism pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Autism pipeline compounds.
The Autism pipeline guide presents information on all active drugs currently being developed for Autism. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Autism pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Autism drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Autism product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Autism pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Autism pipeline report includes-
Autism Report Description-
The 2019 pipeline study on Autism pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Autism pipeline compounds.
The Autism pipeline guide presents information on all active drugs currently being developed for Autism. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Autism pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Autism drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Autism product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Autism pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Autism pipeline report includes-
- An overview of Autism disease including symptoms, causes, diagnosis and available treatment options is provided.
- Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
- Phase wise count of Autism pipeline
- Company wise list of Autism pipeline
- Mechanism of Action wise Autism pipeline
- For each pipeline candidate, the following details are provided
- Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
- Current status of development
- Drug overview
- Mechanism of Action
- Pre-clinical and Clinical Trials/Results
- Company Overview and Recent Developments
- The report is designed to help industry executives promote the success and continued growth of their organizations
- Get clear understanding of the entire Autism pipeline, with details on active projects
- Stay ahead of the competition through comprehensive knowledge of Autism pipeline progress
- Get in detail information of each product with updated information on each project along with key milestones
- Gain clear insights into companies participating in Autism pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. GLOBAL AUTISM PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology
3. EXECUTIVE SUMMARY
3.1 Autism Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase
3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase
3.3.2 Pre-registration
3.4 Companies involved in Autism pipeline, H1- 2019
3.5 Mechanism of Action wise Autism Pipeline Candidates
4 4D PHARMA PLC AUTISM PIPELINE DETAILS
4.1 4D Pharma PLC Business Profile
4.2 4D Pharma PLC Autism Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5 AGENEBIO INC AUTISM PIPELINE DETAILS
5.1 AgeneBio Inc Business Profile
5.2 AgeneBio Inc Autism Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6 APET HOLDING BV AUTISM PIPELINE DETAILS
6.1 APeT Holding BV Business Profile
6.2 APeT Holding BV Autism Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7 AXIAL BIOTHERAPEUTICS AUTISM PIPELINE DETAILS
7.1 Axial Biotherapeutics Business Profile
7.2 Axial Biotherapeutics Autism Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8 AXIM BIOTECH IN AUTISM PIPELINE DETAILS
8.1 Axim Biotech In Business Profile
8.2 Axim Biotech In Autism Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9 BANTAM PHARMACEUTICAL LLC AUTISM PIPELINE DETAILS
9.1 Bantam Pharmaceutical LLC Business Profile
9.2 Bantam Pharmaceutical LLC Autism Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10 BIOHEALTHONOMICS INC AUTISM PIPELINE DETAILS
10.1 BioHealthonomics Inc Business Profile
10.2 BioHealthonomics Inc Autism Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11 BRAINSTORM CELL THERAPEUTICS INC AUTISM PIPELINE DETAILS
11.1 BrainStorm Cell Therapeutics Inc Business Profile
11.2 BrainStorm Cell Therapeutics Inc Autism Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12 CANNABIS SCIENCE INC AUTISM PIPELINE DETAILS
12.1 cannabis science Inc Business Profile
12.2 cannabis science Inc Autism Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13 CENNERV PHARMA (S) PTE LTD AUTISM PIPELINE DETAILS
13.1 Cennerv Pharma (S) Pte Ltd Business Profile
13.2 Cennerv Pharma (S) Pte Ltd Autism Drug Details
13.3 Drug Snapshot
13.3.1 Originator
13.3.2 Collaborator/Co-Developer
13.3.3 Route of Administration
13.3.4 Orphan Drug/Fast Track/Special Designation
13.3.5 Geography
13.3.6 Type of Molecular Entity
13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments
14 CORONIS NEUROSCIENCES LTD AUTISM PIPELINE DETAILS
14.1 Coronis NeuroSciences Ltd Business Profile
14.2 Coronis NeuroSciences Ltd Autism Drug Details
14.3 Drug Snapshot
14.3.1 Originator
14.3.2 Collaborator/Co-Developer
14.3.3 Route of Administration
14.3.4 Orphan Drug/Fast Track/Special Designation
14.3.5 Geography
14.3.6 Type of Molecular Entity
14.3.7 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments
15 CUREMARK LLC AUTISM PIPELINE DETAILS
15.1 Curemark LLC Business Profile
15.2 Curemark LLC Autism Drug Details
15.3 Drug Snapshot
15.3.1 Originator
15.3.2 Collaborator/Co-Developer
15.3.3 Route of Administration
15.3.4 Orphan Drug/Fast Track/Special Designation
15.3.5 Geography
15.3.6 Type of Molecular Entity
15.3.7 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments
16 CYTOCOM INC AUTISM PIPELINE DETAILS
16.1 Cytocom Inc Business Profile
16.2 Cytocom Inc Autism Drug Details
16.3 Drug Snapshot
16.3.1 Originator
16.3.2 Collaborator/Co-Developer
16.3.3 Route of Administration
16.3.4 Orphan Drug/Fast Track/Special Designation
16.3.5 Geography
16.3.6 Type of Molecular Entity
16.3.7 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments
17 EVGEN PHARMA PLC AUTISM PIPELINE DETAILS
17.1 Evgen Pharma Plc Business Profile
17.2 Evgen Pharma Plc Autism Drug Details
17.3 Drug Snapshot
17.3.1 Originator
17.3.2 Collaborator/Co-Developer
17.3.3 Route of Administration
17.3.4 Orphan Drug/Fast Track/Special Designation
17.3.5 Geography
17.3.6 Type of Molecular Entity
17.3.7 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments
18 F. HOFFMANN-LA ROCHE LTD AUTISM PIPELINE DETAILS
18.1 F. Hoffmann-La Roche Ltd Business Profile
18.2 F. Hoffmann-La Roche Ltd Autism Drug Details
18.3 Drug Snapshot
18.3.1 Originator
18.3.2 Collaborator/Co-Developer
18.3.3 Route of Administration
18.3.4 Orphan Drug/Fast Track/Special Designation
18.3.5 Geography
18.3.6 Type of Molecular Entity
18.3.7 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments
19 GW PHARMACEUTICALS PLC AUTISM PIPELINE DETAILS
19.1 GW Pharmaceuticals Plc Business Profile
19.2 GW Pharmaceuticals Plc Autism Drug Details
19.3 Drug Snapshot
19.3.1 Originator
19.3.2 Collaborator/Co-Developer
19.3.3 Route of Administration
19.3.4 Orphan Drug/Fast Track/Special Designation
19.3.5 Geography
19.3.6 Type of Molecular Entity
19.3.7 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments
20 HEPTARES THERAPEUTICS LTD AUTISM PIPELINE DETAILS
20.1 Heptares Therapeutics Ltd Business Profile
20.2 Heptares Therapeutics Ltd Autism Drug Details
20.3 Drug Snapshot
20.3.1 Originator
20.3.2 Collaborator/Co-Developer
20.3.3 Route of Administration
20.3.4 Orphan Drug/Fast Track/Special Designation
20.3.5 Geography
20.3.6 Type of Molecular Entity
20.3.7 Current Status
20.4 Drug Overview
20.5 Drug Mechanism of Action
20.6 Clinical/Pre-clinical Trial Details
20.7 Latest Drug Developments
21 IMMURON LTD AUTISM PIPELINE DETAILS
21.1 Immuron Ltd Business Profile
21.2 Immuron Ltd Autism Drug Details
21.3 Drug Snapshot
21.3.1 Originator
21.3.2 Collaborator/Co-Developer
21.3.3 Route of Administration
21.3.4 Orphan Drug/Fast Track/Special Designation
21.3.5 Geography
21.3.6 Type of Molecular Entity
21.3.7 Current Status
21.4 Drug Overview
21.5 Drug Mechanism of Action
21.6 Clinical/Pre-clinical Trial Details
21.7 Latest Drug Developments
22 INTRA-CELLULAR THERAPIES INC AUTISM PIPELINE DETAILS
22.1 Intra-Cellular Therapies Inc Business Profile
22.2 Intra-Cellular Therapies Inc Autism Drug Details
22.3 Drug Snapshot
22.3.1 Originator
22.3.2 Collaborator/Co-Developer
22.3.3 Route of Administration
22.3.4 Orphan Drug/Fast Track/Special Designation
22.3.5 Geography
22.3.6 Type of Molecular Entity
22.3.7 Current Status
22.4 Drug Overview
22.5 Drug Mechanism of Action
22.6 Clinical/Pre-clinical Trial Details
22.7 Latest Drug Developments
23 MEDDAY SA AUTISM PIPELINE DETAILS
23.1 MedDay SA Business Profile
23.2 MedDay SA Autism Drug Details
23.3 Drug Snapshot
23.3.1 Originator
23.3.2 Collaborator/Co-Developer
23.3.3 Route of Administration
23.3.4 Orphan Drug/Fast Track/Special Designation
23.3.5 Geography
23.3.6 Type of Molecular Entity
23.3.7 Current Status
23.4 Drug Overview
23.5 Drug Mechanism of Action
23.6 Clinical/Pre-clinical Trial Details
23.7 Latest Drug Developments
24 NEUROCHLORE AUTISM PIPELINE DETAILS
24.1 Neurochlore Business Profile
24.2 Neurochlore Autism Drug Details
24.3 Drug Snapshot
24.3.1 Originator
24.3.2 Collaborator/Co-Developer
24.3.3 Route of Administration
24.3.4 Orphan Drug/Fast Track/Special Designation
24.3.5 Geography
24.3.6 Type of Molecular Entity
24.3.7 Current Status
24.4 Drug Overview
24.5 Drug Mechanism of Action
24.6 Clinical/Pre-clinical Trial Details
24.7 Latest Drug Developments
25 OMEROS CORPORATION AUTISM PIPELINE DETAILS
25.1 Omeros Corporation Business Profile
25.2 Omeros Corporation Autism Drug Details
25.3 Drug Snapshot
25.3.1 Originator
25.3.2 Collaborator/Co-Developer
25.3.3 Route of Administration
25.3.4 Orphan Drug/Fast Track/Special Designation
25.3.5 Geography
25.3.6 Type of Molecular Entity
25.3.7 Current Status
25.4 Drug Overview
25.5 Drug Mechanism of Action
25.6 Clinical/Pre-clinical Trial Details
25.7 Latest Drug Developments
26 OPTINOSE US INC AUTISM PIPELINE DETAILS
26.1 OptiNose US Inc Business Profile
26.2 OptiNose US Inc Autism Drug Details
26.3 Drug Snapshot
26.3.1 Originator
26.3.2 Collaborator/Co-Developer
26.3.3 Route of Administration
26.3.4 Orphan Drug/Fast Track/Special Designation
26.3.5 Geography
26.3.6 Type of Molecular Entity
26.3.7 Current Status
26.4 Drug Overview
26.5 Drug Mechanism of Action
26.6 Clinical/Pre-clinical Trial Details
26.7 Latest Drug Developments
27 OVENSA INC AUTISM PIPELINE DETAILS
27.1 Ovensa Inc Business Profile
27.2 Ovensa Inc Autism Drug Details
27.3 Drug Snapshot
27.3.1 Originator
27.3.2 Collaborator/Co-Developer
27.3.3 Route of Administration
27.3.4 Orphan Drug/Fast Track/Special Designation
27.3.5 Geography
27.3.6 Type of Molecular Entity
27.3.7 Current Status
27.4 Drug Overview
27.5 Drug Mechanism of Action
27.6 Clinical/Pre-clinical Trial Details
27.7 Latest Drug Developments
28 PANORAMA RESEARCH INC AUTISM PIPELINE DETAILS
28.1 Panorama Research Inc Business Profile
28.2 Panorama Research Inc Autism Drug Details
28.3 Drug Snapshot
28.3.1 Originator
28.3.2 Collaborator/Co-Developer
28.3.3 Route of Administration
28.3.4 Orphan Drug/Fast Track/Special Designation
28.3.5 Geography
28.3.6 Type of Molecular Entity
28.3.7 Current Status
28.4 Drug Overview
28.5 Drug Mechanism of Action
28.6 Clinical/Pre-clinical Trial Details
28.7 Latest Drug Developments
29 PARK ACTIVE MOLECULES AUTISM PIPELINE DETAILS
29.1 Park Active Molecules Business Profile
29.2 Park Active Molecules Autism Drug Details
29.3 Drug Snapshot
29.3.1 Originator
29.3.2 Collaborator/Co-Developer
29.3.3 Route of Administration
29.3.4 Orphan Drug/Fast Track/Special Designation
29.3.5 Geography
29.3.6 Type of Molecular Entity
29.3.7 Current Status
29.4 Drug Overview
29.5 Drug Mechanism of Action
29.6 Clinical/Pre-clinical Trial Details
29.7 Latest Drug Developments
30 RESPIRERX PHARMACEUTICALS INC AUTISM PIPELINE DETAILS
30.1 RespireRx Pharmaceuticals Inc Business Profile
30.2 RespireRx Pharmaceuticals Inc Autism Drug Details
30.3 Drug Snapshot
30.3.1 Originator
30.3.2 Collaborator/Co-Developer
30.3.3 Route of Administration
30.3.4 Orphan Drug/Fast Track/Special Designation
30.3.5 Geography
30.3.6 Type of Molecular Entity
30.3.7 Current Status
30.4 Drug Overview
30.5 Drug Mechanism of Action
30.6 Clinical/Pre-clinical Trial Details
30.7 Latest Drug Developments
31 REVIVA PHARMACEUTICALS INC AUTISM PIPELINE DETAILS
31.1 Reviva Pharmaceuticals Inc Business Profile
31.2 Reviva Pharmaceuticals Inc Autism Drug Details
31.3 Drug Snapshot
31.3.1 Originator
31.3.2 Collaborator/Co-Developer
31.3.3 Route of Administration
31.3.4 Orphan Drug/Fast Track/Special Designation
31.3.5 Geography
31.3.6 Type of Molecular Entity
31.3.7 Current Status
31.4 Drug Overview
31.5 Drug Mechanism of Action
31.6 Clinical/Pre-clinical Trial Details
31.7 Latest Drug Developments
32 ROGCON U.R. INC AUTISM PIPELINE DETAILS
32.1 RogCon U.R. Inc Business Profile
32.2 RogCon U.R. Inc Autism Drug Details
32.3 Drug Snapshot
32.3.1 Originator
32.3.2 Collaborator/Co-Developer
32.3.3 Route of Administration
32.3.4 Orphan Drug/Fast Track/Special Designation
32.3.5 Geography
32.3.6 Type of Molecular Entity
32.3.7 Current Status
32.4 Drug Overview
32.5 Drug Mechanism of Action
32.6 Clinical/Pre-clinical Trial Details
32.7 Latest Drug Developments
33 RUGEN THERAPEUTICS R&D (SHANGHAI) CO LTD AUTISM PIPELINE DETAILS
33.1 Rugen Therapeutics R&D (Shanghai) Co Ltd Business Profile
33.2 Rugen Therapeutics R&D (Shanghai) Co Ltd Autism Drug Details
33.3 Drug Snapshot
33.3.1 Originator
33.3.2 Collaborator/Co-Developer
33.3.3 Route of Administration
33.3.4 Orphan Drug/Fast Track/Special Designation
33.3.5 Geography
33.3.6 Type of Molecular Entity
33.3.7 Current Status
33.4 Drug Overview
33.5 Drug Mechanism of Action
33.6 Clinical/Pre-clinical Trial Details
33.7 Latest Drug Developments
34 SECOND GENOME INC AUTISM PIPELINE DETAILS
34.1 Second Genome Inc Business Profile
34.2 Second Genome Inc Autism Drug Details
34.3 Drug Snapshot
34.3.1 Originator
34.3.2 Collaborator/Co-Developer
34.3.3 Route of Administration
34.3.4 Orphan Drug/Fast Track/Special Designation
34.3.5 Geography
34.3.6 Type of Molecular Entity
34.3.7 Current Status
34.4 Drug Overview
34.5 Drug Mechanism of Action
34.6 Clinical/Pre-clinical Trial Details
34.7 Latest Drug Developments
35 SEROPEUTICS LLC AUTISM PIPELINE DETAILS
35.1 Seropeutics LLC Business Profile
35.2 Seropeutics LLC Autism Drug Details
35.3 Drug Snapshot
35.3.1 Originator
35.3.2 Collaborator/Co-Developer
35.3.3 Route of Administration
35.3.4 Orphan Drug/Fast Track/Special Designation
35.3.5 Geography
35.3.6 Type of Molecular Entity
35.3.7 Current Status
35.4 Drug Overview
35.5 Drug Mechanism of Action
35.6 Clinical/Pre-clinical Trial Details
35.7 Latest Drug Developments
36 STEM CELL MEDICINE LTD AUTISM PIPELINE DETAILS
36.1 Stem Cell Medicine Ltd Business Profile
36.2 Stem Cell Medicine Ltd Autism Drug Details
36.3 Drug Snapshot
36.3.1 Originator
36.3.2 Collaborator/Co-Developer
36.3.3 Route of Administration
36.3.4 Orphan Drug/Fast Track/Special Designation
36.3.5 Geography
36.3.6 Type of Molecular Entity
36.3.7 Current Status
36.4 Drug Overview
36.5 Drug Mechanism of Action
36.6 Clinical/Pre-clinical Trial Details
36.7 Latest Drug Developments
37 SUMITOMO CHEMICAL CO LTD AUTISM PIPELINE DETAILS
37.1 Sumitomo Chemical Co Ltd Business Profile
37.2 Sumitomo Chemical Co Ltd Autism Drug Details
37.3 Drug Snapshot
37.3.1 Originator
37.3.2 Collaborator/Co-Developer
37.3.3 Route of Administration
37.3.4 Orphan Drug/Fast Track/Special Designation
37.3.5 Geography
37.3.6 Type of Molecular Entity
37.3.7 Current Status
37.4 Drug Overview
37.5 Drug Mechanism of Action
37.6 Clinical/Pre-clinical Trial Details
37.7 Latest Drug Developments
38 SYSTEM1 BIOSCIENCES INC AUTISM PIPELINE DETAILS
38.1 System1 Biosciences Inc Business Profile
38.2 System1 Biosciences Inc Autism Drug Details
38.3 Drug Snapshot
38.3.1 Originator
38.3.2 Collaborator/Co-Developer
38.3.3 Route of Administration
38.3.4 Orphan Drug/Fast Track/Special Designation
38.3.5 Geography
38.3.6 Type of Molecular Entity
38.3.7 Current Status
38.4 Drug Overview
38.5 Drug Mechanism of Action
38.6 Clinical/Pre-clinical Trial Details
38.7 Latest Drug Developments
39 TRANSLATIONAL BIOSCIENCES AUTISM PIPELINE DETAILS
39.1 Translational Biosciences Business Profile
39.2 Translational Biosciences Autism Drug Details
39.3 Drug Snapshot
39.3.1 Originator
39.3.2 Collaborator/Co-Developer
39.3.3 Route of Administration
39.3.4 Orphan Drug/Fast Track/Special Designation
39.3.5 Geography
39.3.6 Type of Molecular Entity
39.3.7 Current Status
39.4 Drug Overview
39.5 Drug Mechanism of Action
39.6 Clinical/Pre-clinical Trial Details
39.7 Latest Drug Developments
40 YAMO PHARMACEUTICALS LLC AUTISM PIPELINE DETAILS
40.1 Yamo Pharmaceuticals LLC Business Profile
40.2 Yamo Pharmaceuticals LLC Autism Drug Details
40.3 Drug Snapshot
40.3.1 Originator
40.3.2 Collaborator/Co-Developer
40.3.3 Route of Administration
40.3.4 Orphan Drug/Fast Track/Special Designation
40.3.5 Geography
40.3.6 Type of Molecular Entity
40.3.7 Current Status
40.4 Drug Overview
40.5 Drug Mechanism of Action
40.6 Clinical/Pre-clinical Trial Details
40.7 Latest Drug Developments
41 ZELDA THERAPEUTICS PTY LTD AUTISM PIPELINE DETAILS
41.1 Zelda Therapeutics Pty Ltd Business Profile
41.2 Zelda Therapeutics Pty Ltd Autism Drug Details
41.3 Drug Snapshot
41.3.1 Originator
41.3.2 Collaborator/Co-Developer
41.3.3 Route of Administration
41.3.4 Orphan Drug/Fast Track/Special Designation
41.3.5 Geography
41.3.6 Type of Molecular Entity
41.3.7 Current Status
41.4 Drug Overview
41.5 Drug Mechanism of Action
41.6 Clinical/Pre-clinical Trial Details
41.7 Latest Drug Developments
42. LATEST AUTISM DRUG PIPELINE DEVELOPMENTS, 2019
43. APPENDIX
43.1 About Us
43.2 Sources and Methodology
43.3 Contact Information
1.1 List of Tables
1.2 List of Figures
2. GLOBAL AUTISM PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology
3. EXECUTIVE SUMMARY
3.1 Autism Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase
3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase
3.3.2 Pre-registration
3.4 Companies involved in Autism pipeline, H1- 2019
3.5 Mechanism of Action wise Autism Pipeline Candidates
4 4D PHARMA PLC AUTISM PIPELINE DETAILS
4.1 4D Pharma PLC Business Profile
4.2 4D Pharma PLC Autism Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5 AGENEBIO INC AUTISM PIPELINE DETAILS
5.1 AgeneBio Inc Business Profile
5.2 AgeneBio Inc Autism Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6 APET HOLDING BV AUTISM PIPELINE DETAILS
6.1 APeT Holding BV Business Profile
6.2 APeT Holding BV Autism Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7 AXIAL BIOTHERAPEUTICS AUTISM PIPELINE DETAILS
7.1 Axial Biotherapeutics Business Profile
7.2 Axial Biotherapeutics Autism Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8 AXIM BIOTECH IN AUTISM PIPELINE DETAILS
8.1 Axim Biotech In Business Profile
8.2 Axim Biotech In Autism Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9 BANTAM PHARMACEUTICAL LLC AUTISM PIPELINE DETAILS
9.1 Bantam Pharmaceutical LLC Business Profile
9.2 Bantam Pharmaceutical LLC Autism Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10 BIOHEALTHONOMICS INC AUTISM PIPELINE DETAILS
10.1 BioHealthonomics Inc Business Profile
10.2 BioHealthonomics Inc Autism Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11 BRAINSTORM CELL THERAPEUTICS INC AUTISM PIPELINE DETAILS
11.1 BrainStorm Cell Therapeutics Inc Business Profile
11.2 BrainStorm Cell Therapeutics Inc Autism Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12 CANNABIS SCIENCE INC AUTISM PIPELINE DETAILS
12.1 cannabis science Inc Business Profile
12.2 cannabis science Inc Autism Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13 CENNERV PHARMA (S) PTE LTD AUTISM PIPELINE DETAILS
13.1 Cennerv Pharma (S) Pte Ltd Business Profile
13.2 Cennerv Pharma (S) Pte Ltd Autism Drug Details
13.3 Drug Snapshot
13.3.1 Originator
13.3.2 Collaborator/Co-Developer
13.3.3 Route of Administration
13.3.4 Orphan Drug/Fast Track/Special Designation
13.3.5 Geography
13.3.6 Type of Molecular Entity
13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments
14 CORONIS NEUROSCIENCES LTD AUTISM PIPELINE DETAILS
14.1 Coronis NeuroSciences Ltd Business Profile
14.2 Coronis NeuroSciences Ltd Autism Drug Details
14.3 Drug Snapshot
14.3.1 Originator
14.3.2 Collaborator/Co-Developer
14.3.3 Route of Administration
14.3.4 Orphan Drug/Fast Track/Special Designation
14.3.5 Geography
14.3.6 Type of Molecular Entity
14.3.7 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments
15 CUREMARK LLC AUTISM PIPELINE DETAILS
15.1 Curemark LLC Business Profile
15.2 Curemark LLC Autism Drug Details
15.3 Drug Snapshot
15.3.1 Originator
15.3.2 Collaborator/Co-Developer
15.3.3 Route of Administration
15.3.4 Orphan Drug/Fast Track/Special Designation
15.3.5 Geography
15.3.6 Type of Molecular Entity
15.3.7 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments
16 CYTOCOM INC AUTISM PIPELINE DETAILS
16.1 Cytocom Inc Business Profile
16.2 Cytocom Inc Autism Drug Details
16.3 Drug Snapshot
16.3.1 Originator
16.3.2 Collaborator/Co-Developer
16.3.3 Route of Administration
16.3.4 Orphan Drug/Fast Track/Special Designation
16.3.5 Geography
16.3.6 Type of Molecular Entity
16.3.7 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments
17 EVGEN PHARMA PLC AUTISM PIPELINE DETAILS
17.1 Evgen Pharma Plc Business Profile
17.2 Evgen Pharma Plc Autism Drug Details
17.3 Drug Snapshot
17.3.1 Originator
17.3.2 Collaborator/Co-Developer
17.3.3 Route of Administration
17.3.4 Orphan Drug/Fast Track/Special Designation
17.3.5 Geography
17.3.6 Type of Molecular Entity
17.3.7 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments
18 F. HOFFMANN-LA ROCHE LTD AUTISM PIPELINE DETAILS
18.1 F. Hoffmann-La Roche Ltd Business Profile
18.2 F. Hoffmann-La Roche Ltd Autism Drug Details
18.3 Drug Snapshot
18.3.1 Originator
18.3.2 Collaborator/Co-Developer
18.3.3 Route of Administration
18.3.4 Orphan Drug/Fast Track/Special Designation
18.3.5 Geography
18.3.6 Type of Molecular Entity
18.3.7 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments
19 GW PHARMACEUTICALS PLC AUTISM PIPELINE DETAILS
19.1 GW Pharmaceuticals Plc Business Profile
19.2 GW Pharmaceuticals Plc Autism Drug Details
19.3 Drug Snapshot
19.3.1 Originator
19.3.2 Collaborator/Co-Developer
19.3.3 Route of Administration
19.3.4 Orphan Drug/Fast Track/Special Designation
19.3.5 Geography
19.3.6 Type of Molecular Entity
19.3.7 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments
20 HEPTARES THERAPEUTICS LTD AUTISM PIPELINE DETAILS
20.1 Heptares Therapeutics Ltd Business Profile
20.2 Heptares Therapeutics Ltd Autism Drug Details
20.3 Drug Snapshot
20.3.1 Originator
20.3.2 Collaborator/Co-Developer
20.3.3 Route of Administration
20.3.4 Orphan Drug/Fast Track/Special Designation
20.3.5 Geography
20.3.6 Type of Molecular Entity
20.3.7 Current Status
20.4 Drug Overview
20.5 Drug Mechanism of Action
20.6 Clinical/Pre-clinical Trial Details
20.7 Latest Drug Developments
21 IMMURON LTD AUTISM PIPELINE DETAILS
21.1 Immuron Ltd Business Profile
21.2 Immuron Ltd Autism Drug Details
21.3 Drug Snapshot
21.3.1 Originator
21.3.2 Collaborator/Co-Developer
21.3.3 Route of Administration
21.3.4 Orphan Drug/Fast Track/Special Designation
21.3.5 Geography
21.3.6 Type of Molecular Entity
21.3.7 Current Status
21.4 Drug Overview
21.5 Drug Mechanism of Action
21.6 Clinical/Pre-clinical Trial Details
21.7 Latest Drug Developments
22 INTRA-CELLULAR THERAPIES INC AUTISM PIPELINE DETAILS
22.1 Intra-Cellular Therapies Inc Business Profile
22.2 Intra-Cellular Therapies Inc Autism Drug Details
22.3 Drug Snapshot
22.3.1 Originator
22.3.2 Collaborator/Co-Developer
22.3.3 Route of Administration
22.3.4 Orphan Drug/Fast Track/Special Designation
22.3.5 Geography
22.3.6 Type of Molecular Entity
22.3.7 Current Status
22.4 Drug Overview
22.5 Drug Mechanism of Action
22.6 Clinical/Pre-clinical Trial Details
22.7 Latest Drug Developments
23 MEDDAY SA AUTISM PIPELINE DETAILS
23.1 MedDay SA Business Profile
23.2 MedDay SA Autism Drug Details
23.3 Drug Snapshot
23.3.1 Originator
23.3.2 Collaborator/Co-Developer
23.3.3 Route of Administration
23.3.4 Orphan Drug/Fast Track/Special Designation
23.3.5 Geography
23.3.6 Type of Molecular Entity
23.3.7 Current Status
23.4 Drug Overview
23.5 Drug Mechanism of Action
23.6 Clinical/Pre-clinical Trial Details
23.7 Latest Drug Developments
24 NEUROCHLORE AUTISM PIPELINE DETAILS
24.1 Neurochlore Business Profile
24.2 Neurochlore Autism Drug Details
24.3 Drug Snapshot
24.3.1 Originator
24.3.2 Collaborator/Co-Developer
24.3.3 Route of Administration
24.3.4 Orphan Drug/Fast Track/Special Designation
24.3.5 Geography
24.3.6 Type of Molecular Entity
24.3.7 Current Status
24.4 Drug Overview
24.5 Drug Mechanism of Action
24.6 Clinical/Pre-clinical Trial Details
24.7 Latest Drug Developments
25 OMEROS CORPORATION AUTISM PIPELINE DETAILS
25.1 Omeros Corporation Business Profile
25.2 Omeros Corporation Autism Drug Details
25.3 Drug Snapshot
25.3.1 Originator
25.3.2 Collaborator/Co-Developer
25.3.3 Route of Administration
25.3.4 Orphan Drug/Fast Track/Special Designation
25.3.5 Geography
25.3.6 Type of Molecular Entity
25.3.7 Current Status
25.4 Drug Overview
25.5 Drug Mechanism of Action
25.6 Clinical/Pre-clinical Trial Details
25.7 Latest Drug Developments
26 OPTINOSE US INC AUTISM PIPELINE DETAILS
26.1 OptiNose US Inc Business Profile
26.2 OptiNose US Inc Autism Drug Details
26.3 Drug Snapshot
26.3.1 Originator
26.3.2 Collaborator/Co-Developer
26.3.3 Route of Administration
26.3.4 Orphan Drug/Fast Track/Special Designation
26.3.5 Geography
26.3.6 Type of Molecular Entity
26.3.7 Current Status
26.4 Drug Overview
26.5 Drug Mechanism of Action
26.6 Clinical/Pre-clinical Trial Details
26.7 Latest Drug Developments
27 OVENSA INC AUTISM PIPELINE DETAILS
27.1 Ovensa Inc Business Profile
27.2 Ovensa Inc Autism Drug Details
27.3 Drug Snapshot
27.3.1 Originator
27.3.2 Collaborator/Co-Developer
27.3.3 Route of Administration
27.3.4 Orphan Drug/Fast Track/Special Designation
27.3.5 Geography
27.3.6 Type of Molecular Entity
27.3.7 Current Status
27.4 Drug Overview
27.5 Drug Mechanism of Action
27.6 Clinical/Pre-clinical Trial Details
27.7 Latest Drug Developments
28 PANORAMA RESEARCH INC AUTISM PIPELINE DETAILS
28.1 Panorama Research Inc Business Profile
28.2 Panorama Research Inc Autism Drug Details
28.3 Drug Snapshot
28.3.1 Originator
28.3.2 Collaborator/Co-Developer
28.3.3 Route of Administration
28.3.4 Orphan Drug/Fast Track/Special Designation
28.3.5 Geography
28.3.6 Type of Molecular Entity
28.3.7 Current Status
28.4 Drug Overview
28.5 Drug Mechanism of Action
28.6 Clinical/Pre-clinical Trial Details
28.7 Latest Drug Developments
29 PARK ACTIVE MOLECULES AUTISM PIPELINE DETAILS
29.1 Park Active Molecules Business Profile
29.2 Park Active Molecules Autism Drug Details
29.3 Drug Snapshot
29.3.1 Originator
29.3.2 Collaborator/Co-Developer
29.3.3 Route of Administration
29.3.4 Orphan Drug/Fast Track/Special Designation
29.3.5 Geography
29.3.6 Type of Molecular Entity
29.3.7 Current Status
29.4 Drug Overview
29.5 Drug Mechanism of Action
29.6 Clinical/Pre-clinical Trial Details
29.7 Latest Drug Developments
30 RESPIRERX PHARMACEUTICALS INC AUTISM PIPELINE DETAILS
30.1 RespireRx Pharmaceuticals Inc Business Profile
30.2 RespireRx Pharmaceuticals Inc Autism Drug Details
30.3 Drug Snapshot
30.3.1 Originator
30.3.2 Collaborator/Co-Developer
30.3.3 Route of Administration
30.3.4 Orphan Drug/Fast Track/Special Designation
30.3.5 Geography
30.3.6 Type of Molecular Entity
30.3.7 Current Status
30.4 Drug Overview
30.5 Drug Mechanism of Action
30.6 Clinical/Pre-clinical Trial Details
30.7 Latest Drug Developments
31 REVIVA PHARMACEUTICALS INC AUTISM PIPELINE DETAILS
31.1 Reviva Pharmaceuticals Inc Business Profile
31.2 Reviva Pharmaceuticals Inc Autism Drug Details
31.3 Drug Snapshot
31.3.1 Originator
31.3.2 Collaborator/Co-Developer
31.3.3 Route of Administration
31.3.4 Orphan Drug/Fast Track/Special Designation
31.3.5 Geography
31.3.6 Type of Molecular Entity
31.3.7 Current Status
31.4 Drug Overview
31.5 Drug Mechanism of Action
31.6 Clinical/Pre-clinical Trial Details
31.7 Latest Drug Developments
32 ROGCON U.R. INC AUTISM PIPELINE DETAILS
32.1 RogCon U.R. Inc Business Profile
32.2 RogCon U.R. Inc Autism Drug Details
32.3 Drug Snapshot
32.3.1 Originator
32.3.2 Collaborator/Co-Developer
32.3.3 Route of Administration
32.3.4 Orphan Drug/Fast Track/Special Designation
32.3.5 Geography
32.3.6 Type of Molecular Entity
32.3.7 Current Status
32.4 Drug Overview
32.5 Drug Mechanism of Action
32.6 Clinical/Pre-clinical Trial Details
32.7 Latest Drug Developments
33 RUGEN THERAPEUTICS R&D (SHANGHAI) CO LTD AUTISM PIPELINE DETAILS
33.1 Rugen Therapeutics R&D (Shanghai) Co Ltd Business Profile
33.2 Rugen Therapeutics R&D (Shanghai) Co Ltd Autism Drug Details
33.3 Drug Snapshot
33.3.1 Originator
33.3.2 Collaborator/Co-Developer
33.3.3 Route of Administration
33.3.4 Orphan Drug/Fast Track/Special Designation
33.3.5 Geography
33.3.6 Type of Molecular Entity
33.3.7 Current Status
33.4 Drug Overview
33.5 Drug Mechanism of Action
33.6 Clinical/Pre-clinical Trial Details
33.7 Latest Drug Developments
34 SECOND GENOME INC AUTISM PIPELINE DETAILS
34.1 Second Genome Inc Business Profile
34.2 Second Genome Inc Autism Drug Details
34.3 Drug Snapshot
34.3.1 Originator
34.3.2 Collaborator/Co-Developer
34.3.3 Route of Administration
34.3.4 Orphan Drug/Fast Track/Special Designation
34.3.5 Geography
34.3.6 Type of Molecular Entity
34.3.7 Current Status
34.4 Drug Overview
34.5 Drug Mechanism of Action
34.6 Clinical/Pre-clinical Trial Details
34.7 Latest Drug Developments
35 SEROPEUTICS LLC AUTISM PIPELINE DETAILS
35.1 Seropeutics LLC Business Profile
35.2 Seropeutics LLC Autism Drug Details
35.3 Drug Snapshot
35.3.1 Originator
35.3.2 Collaborator/Co-Developer
35.3.3 Route of Administration
35.3.4 Orphan Drug/Fast Track/Special Designation
35.3.5 Geography
35.3.6 Type of Molecular Entity
35.3.7 Current Status
35.4 Drug Overview
35.5 Drug Mechanism of Action
35.6 Clinical/Pre-clinical Trial Details
35.7 Latest Drug Developments
36 STEM CELL MEDICINE LTD AUTISM PIPELINE DETAILS
36.1 Stem Cell Medicine Ltd Business Profile
36.2 Stem Cell Medicine Ltd Autism Drug Details
36.3 Drug Snapshot
36.3.1 Originator
36.3.2 Collaborator/Co-Developer
36.3.3 Route of Administration
36.3.4 Orphan Drug/Fast Track/Special Designation
36.3.5 Geography
36.3.6 Type of Molecular Entity
36.3.7 Current Status
36.4 Drug Overview
36.5 Drug Mechanism of Action
36.6 Clinical/Pre-clinical Trial Details
36.7 Latest Drug Developments
37 SUMITOMO CHEMICAL CO LTD AUTISM PIPELINE DETAILS
37.1 Sumitomo Chemical Co Ltd Business Profile
37.2 Sumitomo Chemical Co Ltd Autism Drug Details
37.3 Drug Snapshot
37.3.1 Originator
37.3.2 Collaborator/Co-Developer
37.3.3 Route of Administration
37.3.4 Orphan Drug/Fast Track/Special Designation
37.3.5 Geography
37.3.6 Type of Molecular Entity
37.3.7 Current Status
37.4 Drug Overview
37.5 Drug Mechanism of Action
37.6 Clinical/Pre-clinical Trial Details
37.7 Latest Drug Developments
38 SYSTEM1 BIOSCIENCES INC AUTISM PIPELINE DETAILS
38.1 System1 Biosciences Inc Business Profile
38.2 System1 Biosciences Inc Autism Drug Details
38.3 Drug Snapshot
38.3.1 Originator
38.3.2 Collaborator/Co-Developer
38.3.3 Route of Administration
38.3.4 Orphan Drug/Fast Track/Special Designation
38.3.5 Geography
38.3.6 Type of Molecular Entity
38.3.7 Current Status
38.4 Drug Overview
38.5 Drug Mechanism of Action
38.6 Clinical/Pre-clinical Trial Details
38.7 Latest Drug Developments
39 TRANSLATIONAL BIOSCIENCES AUTISM PIPELINE DETAILS
39.1 Translational Biosciences Business Profile
39.2 Translational Biosciences Autism Drug Details
39.3 Drug Snapshot
39.3.1 Originator
39.3.2 Collaborator/Co-Developer
39.3.3 Route of Administration
39.3.4 Orphan Drug/Fast Track/Special Designation
39.3.5 Geography
39.3.6 Type of Molecular Entity
39.3.7 Current Status
39.4 Drug Overview
39.5 Drug Mechanism of Action
39.6 Clinical/Pre-clinical Trial Details
39.7 Latest Drug Developments
40 YAMO PHARMACEUTICALS LLC AUTISM PIPELINE DETAILS
40.1 Yamo Pharmaceuticals LLC Business Profile
40.2 Yamo Pharmaceuticals LLC Autism Drug Details
40.3 Drug Snapshot
40.3.1 Originator
40.3.2 Collaborator/Co-Developer
40.3.3 Route of Administration
40.3.4 Orphan Drug/Fast Track/Special Designation
40.3.5 Geography
40.3.6 Type of Molecular Entity
40.3.7 Current Status
40.4 Drug Overview
40.5 Drug Mechanism of Action
40.6 Clinical/Pre-clinical Trial Details
40.7 Latest Drug Developments
41 ZELDA THERAPEUTICS PTY LTD AUTISM PIPELINE DETAILS
41.1 Zelda Therapeutics Pty Ltd Business Profile
41.2 Zelda Therapeutics Pty Ltd Autism Drug Details
41.3 Drug Snapshot
41.3.1 Originator
41.3.2 Collaborator/Co-Developer
41.3.3 Route of Administration
41.3.4 Orphan Drug/Fast Track/Special Designation
41.3.5 Geography
41.3.6 Type of Molecular Entity
41.3.7 Current Status
41.4 Drug Overview
41.5 Drug Mechanism of Action
41.6 Clinical/Pre-clinical Trial Details
41.7 Latest Drug Developments
42. LATEST AUTISM DRUG PIPELINE DEVELOPMENTS, 2019
43. APPENDIX
43.1 About Us
43.2 Sources and Methodology
43.3 Contact Information
